- Home
- KFS vs AVIR Comparison
KFS vs AVIR Comparison
Compare KFS & AVIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KFS
- AVIR
- Stock Information
- Founded
- KFS 1989
- AVIR 2012
- Country
- KFS United States
- AVIR United States
- Employees
- KFS N/A
- AVIR N/A
- Industry
- KFS Property-Casualty Insurers
- AVIR Medicinal Chemicals and Botanical Products
- Sector
- KFS Finance
- AVIR Health Care
- Exchange
- KFS Nasdaq
- AVIR Nasdaq
- Market Cap
- KFS 223.3M
- AVIR 251.7M
- IPO Year
- KFS 1996
- AVIR 2020
- Fundamental
- Price
- KFS $7.66
- AVIR $3.09
- Analyst Decision
- KFS
- AVIR Hold
- Analyst Count
- KFS 0
- AVIR 1
- Target Price
- KFS N/A
- AVIR $6.88
- AVG Volume (30 Days)
- KFS 22.3K
- AVIR 318.0K
- Earning Date
- KFS 03-04-2025
- AVIR 03-03-2025
- Dividend Yield
- KFS N/A
- AVIR N/A
- EPS Growth
- KFS N/A
- AVIR N/A
- EPS
- KFS N/A
- AVIR N/A
- Revenue
- KFS $108,627,000.00
- AVIR N/A
- Revenue This Year
- KFS N/A
- AVIR N/A
- Revenue Next Year
- KFS N/A
- AVIR N/A
- P/E Ratio
- KFS N/A
- AVIR N/A
- Revenue Growth
- KFS 2.02
- AVIR N/A
- 52 Week Low
- KFS $7.60
- AVIR $2.75
- 52 Week High
- KFS $9.58
- AVIR $4.60
- Technical
- Relative Strength Index (RSI)
- KFS 33.79
- AVIR 48.26
- Support Level
- KFS $7.73
- AVIR $3.04
- Resistance Level
- KFS $8.00
- AVIR $3.25
- Average True Range (ATR)
- KFS 0.18
- AVIR 0.13
- MACD
- KFS -0.02
- AVIR 0.01
- Stochastic Oscillator
- KFS 10.17
- AVIR 54.29
About KFS Kingsway Financial Services Inc. (DE)
Kingsway Financial Services Inc through subsidiaries operates in the extended warranty and business services industries in the United States. The company operates through segments namely, Extended Warranty and Kingsway Search Xcelerator. The Extended Warranty segment provides after-market vehicle protection services distributed by credit unions. The firm generates maximum revenue from the Extended Warranty segment in the form of Service fee and commission income.
About AVIR Atea Pharmaceuticals Inc.
Atea Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing antiviral therapeutics to improve the lives of patients suffering from serious viral infections. The company is developing its product candidate, bemnifosbuvir, for the treatment of COVID-19, the disease caused by infection with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and its variants and also developing bemnifosbuvir in combination with ruzasvir for the treatment of Hepatitis C (HCV).